

Ritlecitinib: Adis Evaluation

Key Points

- A kinase inhibitor being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn's disease
- Received its first approval on 23 June 2023 in the USA
- Approved for the treatment of severe alopecia areata in adults and adolescents 12 years and older

Summary

Ritlecitinib (LITFULO™), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn's disease. On 23 June 2023, ritlecitinib received approval in the USA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Ritlecitinib is under regulatory review for alopecia areata in the EU, the UK, China and Japan.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.